Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol and Nicotinamide Riboside for Exercise Intolerance in Cystic Fibrosis
NCT04166396Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Feb 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of resveratrol and nicotinamide riboside in cystic fibrosis (CF) (4 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Change in Sirtuin1 at 20 weeks. Started Feb 2020; status: completed.
02
Drugs
resveratrolnicotinamide riboside
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04166396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166396.